NCT07463235 2026-03-13
SPARAGMOS
University of Sao Paulo General Hospital
Phase 3 Recruiting
Clinical Trials
11 trialsNCT03038308 2024-06-04
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
Columbia University
Phase 1/2 Completed
NCT00601289 2020-07-31
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT04107480 2020-07-20
PRolaCT - Three Prolactinoma RCTs
Leiden University Medical Center
Phase 4 Recruiting
NCT03457389 2020-03-18
Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
Seoul National University Hospital
Phase NA Unknown
NCT03717454 2018-11-20
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
Ruijin Hospital
Phase NA Unknown
NCT03400865 2018-10-16
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
Ruijin Hospital
Phase NA Unknown
NCT03353025 2017-11-24
TNAPA
First Affiliated Hospital, Sun Yat-Sen University
Phase NA Unknown
NCT01620138 2016-08-22
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Universidade Federal do Rio de Janeiro
Phase 2/3 Completed
NCT01775332 2015-07-31
Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
Unity Health Toronto
Phase NA Unknown
NCT00697814 2008-06-16
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism
Federal University of São Paulo
Phase 2 Completed